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Summary. When developing a new medicine for children, the potential to extrapolate from adult
efficacy data is well recognized. However, significant assumptions about the similarity of adults
and children are needed for extrapolations to be biologically plausible. One such assumption is
that of similar exposure–response (E–R-) relationships. Motivated by applications to antiepilep-
tic drug development, we consider how data that are available from existing trials of adults
and adolescents can be used to quantify prior uncertainty about whether E–R-relationships are
similar in adults and younger children.A Bayesian multivariate meta-analytic model is fitted to ex-
isting E–R-data and adjusted for external biases that arise because these data are not perfectly
relevant to the comparison of interest. We propose a strategy for eliciting expert prior opinion
on external biases. From the bias-adjusted meta-analysis, we derive prior distributions quanti-
fying our uncertainty about the degree of similarity between E–R-relationships for adults and
younger children. Using these we calculate the prior probability that average pharmacodynamic
responses in adults and younger children, both on placebo and at an effective concentration,
are sufficiently similar to justify a complete extrapolation of efficacy data. A simulation study is
performed to evaluate the operating characteristics of the approach proposed.
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1. Introduction
Leveraging existing data to optimize the design of a drugdevelopment programme is particularly
appropriate when we develop medicines for small or vulnerable populations, such as children.
The European Medicines Agency (EMA) deﬁnes extrapolation as
‘: : : extending information and conclusions available from studies in one or more subgroups of the
patient population (source population) : : : to make inferences for another subgroup of the population
(target population): : :’
(EuropeanMedicines Agency, 2013, 2017). We focus on the extrapolation of adult efﬁcacy data
to children. Wadsworth et al. (2016a) reported the ﬁndings of a systematic review of statistical
methods that are relevant for extrapolating efﬁcacy and other data from adults to children.
Gamalo-Siebers et al. (2017) illustrated methods that use adult data to design improved pae-
diatric programmes and Petit et al. (2018) proposed a method for the design and analysis of
paediatric dose-ﬁnding trials, with the dose range calculated by extrapolating from adult phar-
macokinetic data.Weber et al. (2018) compared the use of Bayesian and frequentist methods for
combining existing adult and paediatric data to inform decision making. Crippa et al. (2018)
developed a one-stage approach to the meta-analysis of aggregated data which can be used
for estimating non-linear dose–response models. Beyond extrapolation from adult data, Zheng
et al. (2019) proposed a Bayesian hierarchical model synthesizing animal and human toxicity
data to learn about the relationship between dose and toxicity risk in a phase I human oncology
trial.
To justify the extrapolation of adult efﬁcacy data to children, we must often make strong
assumptions about the similarity of age groups in terms of disease progression, response to
intervention and exposure–response (E–R-) relationships which we take to link a single out-
come measure to a single summary of exposure. These assumptions are made explicit in the
paediatric decision tree (see Food and Drug Administration (2003)) where judgements about
the plausibility of each aspect of similarity determine whether, in the terminology of Dunne
et al. (2011), a ‘complete’, ‘partial’ or ‘no’ extrapolation strategy is adopted. Fig. 1 explains
the implications of the extrapolation strategy for the data that are generated in paediatrics.
Safety data are required regardless of the extrapolation strategy that is adopted. Dunne et al.
(2011) reviewed 370 paediatric studies submitted to the US Food and Drug Administration
between 1998 and 2008 to identify cases in which efﬁcacy data were extrapolated: of the 166
drug products that were considered, 14.5% followed a complete extrapolation strategy, 68% a
partial extrapolation strategy and 17.5% did not extrapolate. Sun et al. (2017), in an update to
this review, considered 388 paediatric studies that were submitted between 2009 and 2014. The
proportion of products using partial extrapolation fell to 29%, whereas the proportions using
no and complete extrapolation rose to 37% and 34% respectively.
Since 2006, the EuropeanUnion paediatric regulation (EuropeanUnion, 2006) hasmandated
that studies that are intended to support licensing of a medicine for children in the European
Union must follow a paediatric investigation plan, which must be agreed ahead of time with the
EuropeanMedicines Agency’s Paediatric Committee.When selecting an extrapolation strategy,
sponsors must ask themselves how plausible assumptions required for extrapolation are, given
the data to hand. Hlavin et al. (2016) used a scepticism factor to represent uncertainty about the
plausibility of complete extrapolation, where this factor could be established from existing data
or expert opinion. This paper presents a framework using existing data to inform a decision
on whether to perform a complete or partial extrapolation of efﬁcacy data from adults to
children. This decision will determine whether the sponsor will collect only pharmacokinetic
data in children to support dose ﬁnding, or both pharmacokinetic and pharmacodynamic data.
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Fig. 1. Extrapolation strategies, assumptions made and required studies, based on the Food and Drug
Administration paediatric decision tree (Food and Drug Administration, 2003) (PK, pharmacokinetic; PD,
pharmacodynamic)
The framework proposed begins with sponsors prespecifying numerical criteria which E–R-
curves in adults and children must satisfy to be deemed ‘similar’. The sponsor can then use
existing information to quantify prior conﬁdence in this degree of similarity.
We propose performing a Bayesian random-effects meta-analysis of existing E–R-data to
derive priors for differences between E–R-relationships in adults and children. When studying
small populations it is likely that few existing studies will be available for synthesis. Furthermore,
‘external biases’ (Turner et al., 2009) may be inherent in the existing data if there are differences
between the source and target populations, e.g. if existing data are measurements on adults and
adolescents but our question is whether E–R-relationships in adults and children aged 2–11
years are similar. This scenario may often arise in practice because drug development in adults
and children is typically staggered. Furthermore, adolescents are also often recruited into adult
trials in therapeutic areas such as epilepsy (Girgis et al., 2010; French et al., 2012;Marson et al.,
2007a,b) and asthma (FitzGerald et al., 2016; O’Byrne et al., 2017). A draft guidance document
for the inclusion of adolescents in adult oncology trials has recently been released by the Food
and Drug Administration (Food and Drug Administration, 2018). To derive prior distribu-
tions for key parameters accounting for external biases, existing data could be downweighted
according to a ﬁxed weight (e.g. Ibrahim and Chen (2000), Tan et al. (2003) and Rietbergen
et al. (2011)) or dynamically downweighted to a degree reﬂecting the commensurability of the
new and existing data (Ibrahim and Chen, 2000; Hobbs et al., 2011; Neuenschwander et al.,
2010). The challenges of dynamic downweighting were noted in Galwey (2017). Alternatively,
one could model the external biases and deﬁne either empirical priors for the bias parameters
(Welton et al., 2009) or elicit expert opinion on them (Turner et al., 2009). We adopt the latter
approach here.
Throughout we illustrate the proposed extrapolation framework with applications to anti-
epileptic drug development. In this setting, there is broad agreement about the acceptability of
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extrapolating efﬁcacy data in adults with partial onset seizures to older children with partial
onset seizures, although there is some uncertainty about what age one can extrapolate down
to (European Medicines Agency, 2010; Pediatric News, 2016; French et al., 2004; Wadsworth
et al., 2016b). This paper proceeds as follows. In Section 2 we deﬁne a Bayesian bias-adjusted
multivariate meta-analytic model to synthesize existing E–R-data and propose a quantitative
criterion for deﬁning similar E–R-relationships in adults and younger children. Section 3 de-
scribes a scheme for eliciting expert opinion on the external biases that may be inherent in
the existing data. In Sections 4 and 5, we report a simulation study that was used to evaluate
properties of our framework before concluding in Section 6 with a discussion.
2. Using existing data to inform an extrapolation decision
2.1. Motivation
Suppose that E–R-data are available from H existing trials which recruited adults and ado-
lescents. Let Yij represent the response of the ith subject in study j, for i = 1, : : : ,Nj, and
j = 1, : : : ,H . Dropping the i- and j-subscripts for clarity, let A be a binary indicator of age
which takes the value 1 for adolescents and 0 otherwise. Let
E.Y/=g−1
(
γ0 +
K∑
k=1
γkxk +γCC+γAA+γICA
)
, .1/
where C is a measure of drug exposure, x1, : : : , xK are baseline covariates (such as weight)
inﬂuencing response and g is the link function of the generalized linear model.
If we can assume that regression parameters remain constant across studies, the relationship
between exposure and the expected pharmacodynamic response, hereafter referred to as the
E–R-‘relationship’ or ‘curve’, is identical in adults andadolescents ifγA =γI=0.Theassumption
of between-trial homogeneity is relaxed in Section 2.3, in which case γA and γI are interpreted
as mean parameters.
To simplify the presentation of our methods, we shall assume throughout that the pharma-
codynamic response of interest is normally distributed and that a generalized linear model is an
adequate description of the underlying E–R-relationship:
Y =γ0 +
K∑
k=1
γkxk +γCC+γAA+γICA+  .2/
where  ∼ N.0,σ2/ is a random error term. Linear models have been used to analyse E–R-
data for the antiepileptic drugs oxcarbazepine (Nedelman et al., 2007) and topiramate (Girgis
et al., 2010) setting Y = log.Z+110/, where Z is the percentage change from baseline in seizure
frequency and C represents the steady state trough concentration under repeated dosing (Cmin).
Consider now the data that we would accumulate if we performed an E–R-study, indexed
by T , in adults and younger children. The International Conference on Harmonisation E11
guidance (International Conference on Harmonisation, 2001) deﬁnes children as aged 2–11
years, and adolescents as 12–16 or 18 years. If we made a complete extrapolation of efﬁcacy
data from adults to younger children, we would not need to perform study T but it is useful to
consider the data that it would generate. Suppose that wemeasure pharmacodynamic responses
YiT , for i=1, : : : ,NT . Again, dropping the subscript i for clarity, let
YT =β0 +
K∑
k=1
βkxkT +βCCT +βAAT +βICT AT + T , .3/
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where T ∼ N.0,σ2/, x1T , : : : , xKT are baseline prognostic covariates deﬁned analogously to
x1, : : : ,xK, CT is a measure of exposure deﬁned similarly to C and AT is a binary age covariate
taking the value 1 for younger children and 0 otherwise.E–R-relationships in adults and younger
children are identical if βA =βI =0.
We relate parameters in the source and target populations described by models (2) and (3) as
βA =γA + δA,
βI =γI + δI:
.4/
Here δA and δI represent external biases arising because E–R-curves in adolescents and younger
children may differ because of the effects of maturation and physical development on drug
absorption, distribution, metabolism and elimination, and on the action of and response to a
drug (Kearns et al., 2003). Stephenson (2005) noted that the responses of adults and children to
many drugs have much in common, although there are exceptions, such as warfarin (Takahashi
et al., 2000) and cyclosporine (Marshall and Kearns, 1999). An alternative to the additive bias
model (4) is a proportional model stipulating βA = δAγA and βI = δIγI (Turner et al., 2009). We
prefer an additive model since there may be differences between adults and younger children
even if no differences between adults and adolescents exist. The existing data DE are said to be
relevant for learning about likely differences between E–R-relationships in adults and younger
children if δA and δI are both close to 0.
2.2. Extrapolation criterion
We propose criteria evaluating whether a summary measure of the distribution of pharmaco-
dynamic responses in adults and younger children on placebo and at an effective exposure are
sufﬁciently similar. Let CÅ denote a level of exposure that is known to be effective in adults, e.g.
the adult EC90, the exposure atwhich the expected adult response is 90%of themaximum. Itmay
be more straightforward to specify equivalence margins with differences between a transformed
outcome in mind. Thus, E–R-curves are said to be similar if
M{h.YT |CT =0;AT =1/}−M{h.YT |CT =0;AT =0/}∈ .−η1, η1/ .5/
and
M{h.YT |CT =CÅ;AT =1/}−M{h.YT |CT =CÅ;AT =0/}∈ .−η2, η2/, .6/
where h.YT |CT ,AT / is a function of the pharmacodynamic response of a subject with observed
exposure CT in age group AT , and M is a measure of location such as the mean or median.
We require the distribution of pharmacodynamic outcomes in adults and younger children
to be similar at the adult effective concentration. This is because, if E–R-relationships are
judged to be similar between these two age groups, a suitable dose for children would be found
by matching exposures. In practice, bounds η1 and η2 would be set on the basis of clinical
judgement. Larger bounds imply that larger differences between the average pharmacodynamic
responses of adults and younger children will be tolerated if we incorrectly perform a complete
extrapolation and dose younger children targeting the adult effective concentration. Although
different equivalence bounds can be applied at CT =0 and CT =CÅ, to simplify we set η1 =η2.
The joint prior probability of extrapolation criteria (5)–(6), denoted by pE, can be used to
measure the prior plausibility of an assumption thatE–R-curves are sufﬁciently similar in adults
and children to justify a complete extrapolation of efﬁcacy data across these age groups.We spec-
ulate that pE in excess of 0.8 or 0.9 would be sufﬁcient to support the immediate adoption of a
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complete extrapolation strategy. Lower probabilities would prompt a sponsor to collect addi-
tional E–R-data in younger children to verify similarities and to facilitate dose ﬁnding, where
the exact sample size could be determined according to an expected value of information calcu-
lation (Willan and Pinto, 2005; Wilson, 2015). A very low value of pE could be consistent either
with extreme uncertainty about the relevance of the existing data or a strong degree of scepticism
about the similarity of E–R-curves. In both cases, the most appropriate strategy would be to
plan an E–R-study in younger children sized to support independent dose ﬁnding in this age
group.
2.3. Bayesian bias-adjusted meta-analytic model for existing data
Webegin the process of quantifyingwhat is knownabout differences between adults and younger
children by performing a Bayesian meta-analysis of adult and adolescent E–R-data to learn
about γA and γI. We assume that individual patient data are available but aggregate data could
beused ifmaximumlikelihoodestimates and their standard errors are available for all parameters
in the linear predictor ofmodel (2). At the ﬁrst level of themodel, data from study j, j=1, : : : ,H ,
enrolling adults and adolescents are modelled as
Yij =γ0j +γCjCij +γAjAij +γIjCijAij + ij, .7/
where ij ∼N.0,σ2/ and for ease of presentationwe assume that the only baseline covariate prog-
nostic for outcome is age. To limit model complexity, we regard γ01, : : : ,γ0H and γC1, : : : ,γCH
as study-speciﬁc intercepts and effects of exposure respectively and make no assumption about
exchangeability.
For the remaining parameters in model (7), we assume that pairs of study-speciﬁc parameters
.γA1,γI1/, : : : , .γAH ,γIH/ are exchangeable and are samples from a bivariate normal random-
effects distribution with mean μ= .γA,γI/ and covariance matrix Σ. One approach would be
to place an inverse Wishart prior on Σ. However, our investigations found that the results of
meta-analyses are very sensitive to the choice of the inverseWishart scale matrix; decreasing the
diagonal elements of this matrix reduces the variances of the marginal posterior distributions
of γA and γI. Gelman (2006) showed that inverse-gamma(", ") priors with "≈ 0 are informa-
tive for variance parameters in hierarchical models and suggested that inverse Wishart prior
distributions for covariance matrices incur similar issues. To avoid this sensitivity, we adopt
an alternative parameterization (Medical Research Council Biostatistics Unit, 2017) for the bi-
variate normal random-effects distribution which gives the analyst more ﬂexibility in how they
specify priors for the variance parameters. For j =1, : : : ,H , we deﬁne
γAj ∼N.γA, ξ21/,
γIj|γAj ∼N{λ0 +λ1.γAj − γ¯A/, ξ22},
where γ¯A = .1=H/ΣγAj, which implies that(
γAj
γIj
)
∼N
{(
γA
γI
)
,
(
ξ21 λ1ξ
2
1
λ1ξ
2
1 ξ
2
2 + ξ21λ21
)}
: .8/
Under this representation, γI =λ0 +λ1.γA − γ¯A/ and we allow for a correlation between γAj
and γIj, for each j =1, : : : ,H .
The meta-analytic model is completed by deﬁning priors for all unknown parameters. For
each j, j = 1, : : : ,H , the study-speciﬁc intercept and effect of exposure, γ0j and γCj, are as-
signed independent N.0, ζ2/ priors. We deﬁne average parameters γ0 and γC as ΣHj=1γ0j=H and
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ΣHj=1γCj=H so that they represent means for the intercept and effect of exposure across the H
existing studies. For the residual precision we stipulate σ−2 ∼gamma.a,b/, with a and b chosen
to deﬁne a weakly informative prior. For the parameters of random-effects distribution (8),
we place an N.0, 100/ prior on γA and specify priors ξ1 ∼ gamma.a1,b1/, ξ2 ∼ gamma.a2,b2/,
λ0 ∼Student-t.μλ0 ,σλ0 , νλ0/ and λ1 ∼N.μλ1 ,σ2λ1/. In the examples that we have considered, we
have chosen hyperparameters to ensure that the prior for the correlation between each pair
.γAj,γIj/ has a bucket shape, placing probability mass at −1 and 1, and furthermore that prior
probabilitymass is placedona rangeof plausible values for the between-trial standarddeviations
of the γAj- and γIj-parameters (Neuenschwander et al., 2010).
TheBayesianmeta-analyticmodel canbeﬁttedbyusingMarkovchainMonteCarlo (MCMC)
sampling. The joint posterior distribution of .γ0,γC,γA,γI/ will not be of a standard form. To
justify a complete extrapolation decision, the prior probability of criteria (5) and (6) would
probably need to be reported in the paediatric investigation plan, trial protocols and journal
publications. Using an approximation to the joint posterior distribution which has a closed
form would allow reviewers of these documents to reproduce pE more easily. Otherwise, one
would need to rerun the original meta-analysis to generate pE, which would require access to
subject level datawhichmaynotbepublicly available.Therefore, to facilitate communicationand
reproducibility of the joint posterior, we approximate it as a ﬁnitemixture ofK four-dimensional
multivariate normal distributions (Schmidli et al., 2014) using the flexmix package (Leisch,
2004; Gru¨n and Leisch, 2007, 2008) in R (R Development Core Team, 2015):
f.γ0,γC,γA,γI|Y1, : : : ,YH/≈
K∑
i=1
ωiφ4.μi,Σi/, .9/
where φ4.μ,Σ/ is the four-dimensional multivariate normal probability density function with
mean μ and variance Σ, and Y1, : : : ,YH are vectors representing the adult and adolescent data
from existing studies 1, : : : ,H . Increasing K in approximation (9) increases the accuracy of
the ﬁnite mixture approximation as measured by the Kullback–Leibler divergence (Kullback
and Leibler, 1951; Schmidli et al., 2014). However, these increases diminish with K and must
be balanced against increases in model complexity. In our investigations, we have found that
setting K=2 in approximation (9) is adequate.
If we consider .γA,γI/ in model (2) to be systematically biased for the parameters .βA,βI/
in model (3), then we can elicit expert opinion on the size of these external biases. We assume
that prior opinion on the bias parameters can be modelled as a bivariate normal distribu-
tion, written as δ ∼N2.ν,Π/, where δ = .δA, δI/. By sampling pairs .γA,γI/ and .δA, δI/ from
f.γ0,γC,γA,γI|Y1, : : : ,YH/ and φ2.ν,Π/ respectively, we can generate samples from the prior
distribution of .βA,βI/ given the existing data. Fitting these Monte Carlo samples by using
maximum likelihood estimation, we obtain the approximate prior
g.βA,βI|Y1, : : : ,YH/=
2∑
i=1
ωi φ2.μi,Σi/: .10/
3. Eliciting prior opinion on external biases
3.1. Overview
In this section we describe our proposal for eliciting an individual expert’s opinion on δA and δI.
We envisage eliciting opinion at a face-to-face meeting of experts by using a two-step process:
ﬁrst elicit the beliefs of individuals; then in a group discussion use behavioural aggregation to
obtain a consensus opinion (Hampson et al., 2014). If experts cannot agree on a consensus prior,
522 I. Wadsworth, L. V. Hampson, T. Jaki, G. J. Sills, A. G. Marson and R. Appleton
mathematical aggregation of individual expert opinion could be considered. Experts should be
subject matter specialists, such as consultant level clinicians with a relevant specialism. We rec-
ommend identifying such individuals through research groups and networks, trying to achieve
a good coverage of potential viewpoints. In this context, we suggest involving clinicians who
specialize in treating adults and those who treat paediatrics so that we can draw on the expe-
rience of both groups to interpret the adult and adolescent data appropriately. Our elicitation
scheme has four components.
(a) Part 1: present to each expert the ﬁtted dose–response curves for adults and adolescents
derived from a meta-analysis of completed trials.
(b) Part 2: elicit each expert’s prior modal guess at the dose–response curve in younger chil-
dren, in light of the data that are presented in part 1.
(c) Part 3: elicit from the expert their uncertainty about their answer to part 2 as a 90%
credible interval.
(d) Part 4: use the expert’s answers to derive a ﬁtted prior for δA and δI. Feed back summaries
of ﬁtted priors for the dose–response relationship in younger children. Allow the expert
to revise their answers until they are happy that their ﬁtted prior captures their beliefs.
Note that we frame elicitation questions in terms of the dose–response, rather than E–R-
relationship, since clinicians are likely to be more familiar expressing beliefs about the former.
In our experience, serum concentrations of antiepileptic (and other drugs) are not typically
measured in routine clinical practice, so clinicians tend to be more familiar with dose than
with concentration. Answers to elicitation questions can be translated to opinions on E–R-
parameters assuming that the relationship between dose and exposure is known. This might
be derived by using existing E–R-data or through a further elicitation exercise with pharmaco-
metricians. In our examples, we assume that dose proportionality holds over the dose range of
interest. Letting d denote dose, we can write exposure as C =κd, with known κ.
3.2. Rationale for the elicitation scheme
We now show that, under certain assumptions, we can deduce, from an expert’s conditional
opinions on the dose–response curve in younger children given in parts 2 and 3 of the elicitation
scheme, the joint prior distribution for .δA, δI/.
It is reasonable to suppose that, when presented with the ﬁtted adult and adolescent dose–
response curves, the expert will take these to be the true response curves for these age groups,
disregardinganyestimation error. Ignoring for themomentbetween-studyheterogeneity inE–R-
parameters, model (2) stipulates that, at dose dÅ, the ﬁtted average pharmacodynamic response
in adults is F1dÆ = γ0 + γCκdÅ and the ﬁtted average response in adolescents is F1dÆ + F2dÆ =
γ0 +γCκdÅ +γA +γIκdÅ. Therefore, from the presentation of the existing data, at dose dÅ an
expert can deduce
(a) the average response in adults, F1dÆ , and
(b) the difference between the adult and adolescent expected responses F2dÆ =γA +γIκdÅ.
Assumingbiasmodel (4) andassumingnodrift in theparametersof theadultE–R-relationship
so that, in a future E–R-study enrolling adults and younger children β0 =γ0 and βC =γC, model
(3) stipulates that the expected response of a younger child given dose dÅ would be
E.YT |AT =1,CT =κdÅ/=γ0 +γCκdÅ +γA + δA + .γI + δI/κdÅ:
Conditioning on what has been learnt from the existing data, we have
E.YT |AT =1,CT =κdÅ/|F1dÆ ,F2dÆ =F1dÆ +F2dÆ + δA + δIκdÅ:
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Assuming that prior opinion on .δA, δI/ is independent of opinion on other E–R model param-
eters and can be modelled as N2.ν,Π/, with ν = .νA, νI/ and
Π=
(
π2A πAI
πAI π
2
I
)
,
then at dose dÅ we obtain
E.YT |AT =1,C =κdÅ/ |F1dÆ ,F2dÆ ∼N{F1dÆ +F2dÆ +νA +νIκdÅ,π2A +2πAIκdÅ +π2I .κdÅ/2}:
In parts 2 and 3 of the elicitation scheme, we ask the expert for their conditional opinion
on the average response of younger children on placebo, a ‘medium’ or a ‘high’ dose, de-
noted by d0, dM and dH respectively. The proposed wording of the elicitation questions is
given in the on-line supplementary appendix A and the Shiny application can be found on
GitHub (https://github.com/iwadsworth/ElicitBiasPrior). In practice, dM and
dH could be chosen on the basis of adult dose-ﬁnding studies or, if the drug has already been
licensed in adults, using World Health Organization lists of deﬁned daily doses (World Health
Organization Collaborating Centre for Drug Statistics Methodology, 2016). If an expert ex-
presses the consistent opinion that the average response in younger children is similar to the
ﬁtted average in adolescents, this suggests that they believe that δA and δI are small, i.e. that
the existing adult and adolescent data are highly relevant for informing our understanding of
likely differences between adults and younger children. Note that the scheme proposed asks for
opinions on the relevance of the existing data after an expert has seen how supportive they are
of a complete extrapolation of efﬁcacy data from adults to adolescents. To increase the credi-
bility of beliefs that are elicited in this way, one could interview independent experts who are
not directly involved with the drug development programme. Furthermore, the assumption that
opinion on .δA, δI/ is independent of opinion on other E–R model parameters is a pragmatic
one which ensures that elicitation questions have a direct interpretation and can be answered
by non-statisticians.
By asking an expert for their best guesses at the average pharmacodynamic responses in chil-
dren on placebo and a ‘high’ dose, we deduce ﬁtted values of νA and νI. To ﬁnd νA, one can
subtract the ﬁtted value of γ0 +γA, obtained from the meta-analysis of existing data, from the
expert’s best guess at the average response on placebo. Meanwhile, νI is obtained by subtract-
ing the ﬁtted value of γC +γI, also obtained from the meta-analysis, from the slope calculated
by dividing the difference between the expert’s best guesses at the expected pharmacodynamic
responses on a high dose and placebo by κdH. An expert’s uncertainty about the average phar-
macodynamic response in younger children on dose dÅ, for dÅ ∈ .d0,dM,dH/, is established by
asking questions to establish the ﬁfth, 25th, 75th and 95th percentiles of their prior distribution
for this quantity. Given values of νA and νI, we can then adapt the approach ofNeuenschwander
et al. (2008) to search over conﬁgurations of π2A, π
2
I and πAI to ﬁnd the triplet which deﬁnes a
positive deﬁnite variancematrix andminimizes the absolute difference betweenpercentiles of the
ﬁtted prior and the expert’s stated percentiles. To ensure positive deﬁniteness, Π is represented
in the optimization routine by using the Cholesky decomposition.
3.3. Example: application to antiepileptic drug development
The prior elicitation protocol and accompanying R Shiny application that are described in the
on-line supplementary appendix A underwent several rounds of testing, with one author (IW)
asking neurologists with experience of treating adult and/or paediatric epilepsy about dose–
response curves for an antiepileptic drug. Testing included face-to-face pilot runs with eight
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neurologists attending the International League Against Epilepsy British and Irish Chapters
Meeting (Dublin, October 2016). The ﬁnal version of the protocol was also piloted on three
neurologists via web conference. The ﬁgures in supplementary appendix B are of the application
tailored to the antiepileptic drug development application.
A few comments on the application of our elicitation scheme to the antiepileptic drug example
are needed. The pharmacodynamic response, Y = log.Z+110/, is the log-transformed percent-
age change in seizure frequency from baseline. Since a log-transformed percentage change is
difﬁcult to give opinions on, we elicited beliefs on the percentage change in seizure frequency
Z instead. It seems natural to think that, if we took an expert’s best guess at the relationship
between dose and E.Z/ and then transformed it, we would obtain their best guess at the rela-
tionship between dose and E.Y/. Therefore, the prior mode for E.Y/ at a particular dose was
obtained by transforming the prior mode of E.Z/. The percentiles of an expert’s prior distribu-
tion for E.Z/ were similarly transformed to obtain percentiles of their prior for E.Y/ (since the
transformation was monotonic).
Using our elicitation procedure and Shiny application, bias priors E1 and E2 below were
elicited from two epileptologists who were presented with simulated individual participant data
on a licensed antiepileptic drug shown inFig. 2. Thesewere generated from the ﬁttedmodels that
were presented in Girgis et al. (2010). Assuming that κ=1, the E–R-relationship is equivalent
to the dose–response relationship:
(a) prior E1, (
δA
δI
)
∼N
{(
0
0
)
,
(
0:1012 0
0 0:0162
)}
;
(b) prior E2, (
δA
δI
)
∼N
{(
0:050
0:003
)
,
(
0:1012 0
0 0:0162
)}
:
Prior E1 reﬂects the opinion that it ismost likely that the average pharmacodynamic responses
of adolescents and younger children are the same. Prior E2 is consistent with the belief that the
E–R-curve in younger children lies slightly above that of adolescents (indicating a worse average
response), so differences between E–R-curves in adults and younger children are larger than
those between adults and adolescents. However, as can be seen from Fig. 2(b), both experts
were uncertain about the dose–response curve in younger children given the existing data. The
implications of this for extrapolation decisions are explored in Section 4.
4. Simulation study
Simulation scenarioswere informedbyapplications to antiepileptic drugdevelopment forpartial
onset seizures (Girgis et al., 2010; Nedelman et al., 2007).
4.1. Epilepsy application extrapolation criterion
In all simulation scenarios, E–R-curves were said to be similar in two age groups if differences
between median percentage changes from baseline in seizure frequency were less than 10%:
M{exp.YT /−110|CT =0;AT =1}−M{exp.YT /−110|CT =0;AT =0}∈ .−10, 10/ .11/
and
M{exp.YT /−110|CT =CÅ;AT =1}−M{exp.YT /−110|CT =CÅ;AT =0}∈ .−10, 10/, .12/
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Fig. 2. (a) Simulated adult ( ) and adolescent ( ) individual participant data and curves of best fit ( ,
adult; , adolescent) and (b) elicited modal values of the dose–response relationship in younger children
( ), with corresponding 90% credible interval ( ), used to derive prior E1: also plotted are adult
( ) and adolescent ( ) curves of best fit obtained from the simulated individual participant data
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where M represents the median and CÅ is the adult EC90. Our choices for η1 and η2 were based
on clinical feedback on acceptable differences in average responses. We wrote the similarity
criteria in terms of the transformed pharmacodynamic end point to make it easier to elicit
similarity bounds. We chose the median as our summary measure of response since, if Y follows
a log-normal distribution with median mY , the median of Z = exp.Y/− 110 is given by mZ =
exp.mY /−110, thus simplifying the mapping of properties from Z to Y.
4.2. Simulating existing E–R-data in adults and adolescents
We simulated the pharmacodynamic responses of adults and adolescents according to model
(7). Setting the residual variance σ2 =0:0243 ensured that the transformed responseZ lay within
±10% of its median given the patient’s age group and level of exposure with probability 0.95.
We simulated age group indicators A ∼Bern.0:15/ so that on average 15% of existing trial
participants were adolescents. This proportion appears reasonable on the basis of the studies
that were cited in Girgis et al. (2010). Furthermore, we assigned 10% of patients in each study
to placebo. For patients who were allocated to the drug, we sampled log.Cmin/ from a normal
distribution with mean log.2:94/ and variance 0.921, truncating samples above by log.17:27/.
In this way, we generated Cmin-values with quartiles and ﬁrst and 99th percentiles similar to
those reported by studies cited in Girgis et al. (2010) where Cmin-values ranged between 0.19
and 17:27μg ml−1.
For each existing study, study-speciﬁc parameters of E–R-model (7) were generated by sam-
pling γ0j ∼N.γ0,σ20/, γCj ∼N.γC,σ2C/ and(
γAj
γIj
)
∼N
{(
γA
γI
)
,
(
σ2A 0
0 σ2I
)}
,
setting γ0 =4:4469 and γC =−0:0627, which are the maximum likelihood estimates of these pa-
rameters taken fromGirgis et al. (2010). Let P and C represent the difference betweenM.Z|A=
1,C/ and M.Z|A=0,C/ when C =0 and C =CÅ respectively. We chose values for γA and γI such
that P and C, when evaluated under these average parameters, spanned a realistic range of
differences. We considered pairs .P, C/∈{.0, 0/, .5, 5/, .10, 10/, .20, 20/, .5, 10/, .5, 20/} which
correspond to the six pairs of .γA,γI/ labelled in Table 1 as E–R-models S1–S6.
Table 1. Population means of the effects of age, γA, and the interaction between age and exposure, γI, for
adults and adolescents in the six E–R simulation models, with the interpretation of each model†
Model γA γI Model interpretation
S1 0 0 Population median pharmacodynamic response identical in adults and
adolescents
S2 0.057 0.006 Small differences between population median pharmacodynamic
responses satisfy criteria (11)–(12)
S3 0.111 0.010 Moderate differences satisfy criteria (11)–(12)
S4 0.211 0.018 Large differences do not satisfy criteria (11)–(12)
S5 0.057 0.014 Small differences between population median pharmacodynamic responses
on placebo; moderate differences at EC90 satisfy criteria (11)–(12)
S6 0.057 0.027 Small differences between population median pharmacodynamic responses
on placebo; large differences at EC90 do not satisfy criterion (12)
†The population median pharmacodynamic response refers to exp.mY /−110, where mY =M.Y/ is calculated by
setting E–R model parameters equal to their population means.
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The variances of study-speciﬁc E–R-parameters were chosen to characterize low, moderate,
high and very high levels of between-trial heterogeneity. We chose σ20 such that a study-speciﬁc
value of M.Z|A = 0,C = 0/ lay within ±10% of the median of Z calculated by setting the
E–R-model parameters equal to their population means with probability 0.6 (very high hetero-
geneity), 0.7 (high), 0.8 (moderate) or 0.95 (low). Fixing σ20, σ
2
C was then set to ensure that the
study-speciﬁc value of M.Z|A=0,C =EC90/ lay within ±10% of the median of Z calculated by
setting the E–R-model parameters equal to their population means with the same probability.
We chose σ2A and σ
2
I to ﬁx the probability that an individual existing trial will be consistent with
an assumption of similar E–R-curves in adults and adolescents according to criteria (11)–(12).
Speciﬁcally, we chose σ2A such that, with probability 0.6, 0.7, 0.8 or 0.95, the true difference in
a study between M.Z|A= 0,C = 0/ and M.Z|A= 1,C = 0/ lay within ±10%. For a particular
choice of σ2A, we then ﬁxed σ
2
I such that, with probability 0.6, 0.7, 0.8 or 0.95, the true differ-
ence between study-speciﬁc values M.Z|A=0,C =EC90/ and M.Z|A=1,C =EC90/ lay within
±10%. Different conﬁgurations of the heterogeneity parameters are listed in Table 2.
Simulation scenarios considered different numbers of existing trials .H =2, 3, 4, 5, 10, 20/ and
numbers of subjects per trial (N = 30, 170). Numbers of existing trials were chosen to explore
a plausible range: Davey et al. (2011) reported that 75% of the 22453 meta-analyses that were
listed in the Cochrane database of systematic reviews at 2011 were based on ﬁve or fewer studies,
and 1% were based on 28 or more. Values of N were informed by four industry-sponsored trials
of an antiepileptic drug, the average sample size of which was 168 patients.
4.3. Meta-analysis of simulated existing E–R-studies
For each of the 288 simulation scenarios, we simulated 1000 sets of trials and ﬁtted the Bayesian
meta-analytic model of Section 2.3 to each data set. All simulations were performed in R (R
Development Core Team, 2015) ﬁtting the meta-analytic model by calling OpenBUGS version
3.2.3 (Lunn et al., 2009) using the R2OpenBUGS package (Sturtz et al., 2005). We ﬁtted the
Bayesian model by running three chains using a thinning rate of 5, running the chain for 30000
iterations including a burn-in of 10000 iterations. The coda package (Plummer et al., 2006) was
then used to extract posterior samples from the OpenBUGS output.
The meta-analytic model was ﬁtted stipulating the priors that are given in Table 3. Hyper-
parameters for ξ1 and ξ2, deﬁning the variability of the random-effects distribution (8), were
chosen so that E.ξ1/ and E.ξ2/ were equal to our choices for the moderate between-trial stan-
dard deviation for γA and γI given in Table 2. Then 95% of the probability mass for the ξ1-prior
was between (0.012, 0.250), and 95% of the probability mass for the ξ2-prior was between
(0.001, 0.050). Therefore, low weight was given to very low and high between-trial variances.We
Table 2. Standard deviations for the intercept σ0 and effects
of exposure, σC, age, σA, and the interaction between age and
exposure, σI, chosen to reflect low, moderate, high and very high
levels of between-trial heterogeneity
Level of heterogeneity σ0 σC σA σI
Low 0.057 0.008 0.059 0.009
Moderate 0.086 0.012 0.091 0.014
High 0.107 0.015 0.113 0.018
Very high 0.132 0.019 0.140 0.023
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Table 3. Prior distributions placed on pa-
rameters of model (7) and random-effects
distribution (8)
Parameter Prior distribution
γ01,: : : ,γ0H N.0, 100/
γC1,: : : ,γCH N.0, 100/
ξ1 gamma(2.097, 23.003)
ξ2 gamma(1.118, 78.149)
λ0 t.0, 0:03, df=3/
λ1 N.0, 1/
repeated some simulations placing gamma(1.5, 3) priors on ξ1 and ξ2, which resulted in a slight
reduction in the probability of extrapolation.
5. Results
5.1. Meta-analysis of existing data
As can be seen from on-line supplementary Tables ST9–ST16, the Bayesian multivariate meta-
analysis of the existing adult and adolescent data produces accurate estimates of γA and γI, with
low bias, empirical standard deviations and mean-squared error in most scenarios. In all cases,
the accuracy increases with the sample size per existing study. Empirical standard deviations
are highest under the highest level of between-trial heterogeneity, but the bias remains small.
The intercept and effect of exposure are also estimated with small bias and high precision (the
results are not presented).
5.2. Effective sample sizes of the approximate joint prior for parameters representing
differences between adults and younger children
On-line supplementary appendix C explores how the average effective sample sizes of the bivari-
ate normal mixture approximation to the joint prior for .βA,βI/ is inﬂuenced by an expert’s un-
certaintyabout thebiasparameters.UnderbiaspriorE1, information fromthe existingadult and
adolescent data is heavily downweighted; for example, if each existing study enrolled170patients,
assuming lowbetween-trial heterogeneity, the effective sample size of the prior for .βA,βI/would
be 24. The effective sample size of the prior for .βA,βI/ increases as prior uncertainty about the
external biases decreases. For more details, the reader is referred to supplementary appendix C.
5.3. Prior probability that E–R-curves are similar in adults and younger children
First we look at how the prior probability of the extrapolation criteria (11)–(12) (referred to
as pE) varies with the true E–R-relationship in adults and adolescents. On-line supplementary
Tables ST17–ST20 present the means and empirical standard deviations of pE for a range of
scenarios. Figs 3(d)–3(f) illustrateE–R-relationships in adults, adolescents and younger children
under simulation models S1, S3 and S4 and bias prior E1. Figs 3(a)–3(c) illustrate how pE
changes as differences between adult and adolescent E–R-relationships increase from none
(model S1), to moderate (model 3) to large (model 4) under bias prior E1. A general trend is that
larger values ofpE are recorded in scenarioswhere the trueE–R-curves in adults and adolescents
are more closely aligned. Under bias prior E1 and models S1 and S3, when differences between
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Fig. 3. (a)–(c) Average prior extrapolation probabilities under bias prior E1 and simulation scenarios S1,
S3 and S4 respectively ( , ˙1 empirical standard deviation of the observed probabilities) and (d)–(f) median
responses in adults, adolescents and younger children under simulation models S1, S3 and S4 respectively:
also plotted are the lower bounds of 90% credible intervals for the median response in younger children,
consistent with bias prior E1 when its variance matrix is unscaled, or scaled by a factor of 0.5 or 2; credible
intervals are calculated conditioning on true values of adult and adolescent E–R-parameters; bars at the
placebo and EC90 represent similarity bounds given criteria (11) and (12)
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adults and adolescents are sufﬁciently small to satisfy criteria (11) and (12), pE increases as N
increases, although differences diminish with H .
Under model S1 and bias prior E1, pE reaches a maximum of 0.572 when the between-trial
heterogeneity is low and data are available from H =20 existing studies, each having recruited
N =170 subjects. Curves representing cases when the bias prior variance matrix is scaled by a
factor of 0.5, 0.01 or 0 show that, if uncertainty about external biases were to be signiﬁcantly
reduced, pE would increase. If the prior variance matrix is scaled by a factor of 0, we take
this to mean that the expert knows that δA = νA and δI = νI; therefore, their joint prior places
probability mass 1 on the conﬁguration .δA, δI/ = .νA, νI/ and assigns zero probability to all
other pairs. For bias prior E1, a scale factor of 0 would reﬂect the opinion that we are certain
that differences between adult and adolescent E–R-curves reﬂect differences between curves for
adults and younger children. There is a question of whether it is plausible that an expert would
be sufﬁciently conﬁdent in their beliefs for us to attain a high value of pE. Suppose that pE =0:8
would be sufﬁcient to support a complete extrapolation strategy. From Fig. 3(a), we see that,
under model S1 with low between-trial heterogeneity and 170 subjects per trial, if we scale the
bias prior variance matrix by 0.5, pE reaches 0.8 when H>5. From Fig. 3(d), we can see what
this scaling factor would correspond to in terms of the level of conﬁdence that an expert must
have in the location of the E–R-curve in younger children. We speculate that experts could have
this level of conﬁdence in practice.With enough existing data and strong, but still feasible, expert
opinion, a high prior extrapolation probability is plausible.
Prior probabilities of extrapolation under models S2, S5 and S6 are provided in the on-line
supplementary materials as Figs SF9–SF11. Similar patterns are seen in the results that are
generated under models S2 and S5 to those under model S1, although values of pE tend to
be lower overall, reﬂecting the larger differences between adult and adolescent E–R-curves. A
similar comment applies to results generated under models S4 and S6.
We have repeated our investigations by using bias prior E2. Comparing results generated
under the two priors, we see that the prior probability of extrapolation under prior E2 is lower
in all scenarios, demonstrating that it is not only an expert’s uncertainty about external biases
which inﬂuences the probability of extrapolation but also the expert’s opinion on the direction
of differences between E–R-curves in adolescents and younger children.
6. Discussion
This paper proposes a quantitative framework for using existing pharmacological data to in-
form our understanding of likely differences between E–R-relationships in adults and younger
children. The prior probability of acceptably small differences between these relationships is
used to inform a decision of whether to perform a complete or partial extrapolation of adult
efﬁcacy data to younger children. Currently, we propose that prior extrapolation probabilities
in excess of 0.8 or 0.9 would support a decision to adopt a complete extrapolation strategy,
although further work will explore whether the choice of this cut-off can be reﬁned and formal-
ized through the use of a decision theoretic argument. Such an approachwould consider various
risks and costs, including the risk to children of incorrectly adopting a complete extrapolation
strategy and the costs to patients and the sponsor of failing to perform a complete extrapolation
when this is appropriate. When it is unclear whether a complete extrapolation strategy should
be adopted or not, one could use an expected value of information analysis (Briggs et al., 2006;
Heath et al., 2017) to quantify the value, in terms of improved decision making, of collecting
varying numbers of additional E–R-data in younger children given the risks that were outlined
above.
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When performing the bias-adjusted meta-analysis on which the prior probability of extrap-
olation is based, it is essential that the studies included should have been identiﬁed through a
process of systematic review according to a prespeciﬁed protocol (Higgins and Green, 2011;
Khan et al., 2011). We suggest that the eligibility criteria for the systematic review should in-
clude trials that recruit patients with the indication of interest, assess the same drug and collect
follow-up data that allow the chosen outcomes to be analysed. To inform expert opinion, during
the elicitation meeting we could broaden out to present data on related drugs or indications.
Our current approach assumes that E–R-relationships can be captured by models which
represent age as a categorical variable, i.e. that assume that there are no important differences
within an age group. Although this assumption will never hold exactly, we do expect it to hold
approximately for suitably deﬁned age groups. If important differences were expected to occur
within an age group, then a more suitable approach would be to consider each homogeneous
age group in turn and to select an extrapolation strategy for each by application of the methods
that were described in Sections 2 and 3. Although themotivating example for this work has been
extrapolating across age groups, a similar framework could be used to inform the extrapolation
of efﬁcacy data across ethnic groups or geographic regions, where subgroups in this setting are
naturally discrete.
In this paper, we have considered the case of linear E–R-models, though generalized linear
models would be accommodated in our framework with appropriate adjustments to the elicita-
tion protocol.However, over the therapeutic windowof interest, theE–R-relationship is likely to
be approximately linear in many cases, even if the complete E–R-relationship follows an Emax
model (Macdougall, 2006): a non-linear model which is often used to model the relationship
between exposure and response. If this is not so, extending to non-linear E–R-models could be
possible, though one would need to consider
(a) how to parameterize the more complex E–R-models for adults, adolescents and younger
children,
(b) how to represent differences between the variousE–R-relationships and to deﬁne decision
criteria governing extrapolation decisions and
(c) how one would devise a scheme to elicit opinion on biases affecting parameters governing
the similarity of E–R-relationships.
Additionally, our prior extrapolation probability would probably need to consider a moderate
exposure level, such as EC50, along with a placebo and a higher exposure.
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